PMID- 32967493
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 61
IP  - 14
DP  - 2020 Dec
TI  - Selection and management of older patients with acute myeloid leukemia treated 
      with glasdegib plus low-dose cytarabine: expert panel review.
PG  - 3287-3305
LID - 10.1080/10428194.2020.1817445 [doi]
AB  - Glasdegib, in combination with low-dose cytarabine (LDAC), is the first 
      smoothened inhibitor approved for treatment of acute myeloid leukemia. Glasdegib 
      plus LDAC is indicated for patients in whom therapy options are limited, e.g. 
      older patients and those ineligible for intensive chemotherapy due to preexisting 
      comorbidities. This review summarizes the recommendations of a panel of 
      hemato-oncologists regarding the selection of patients best suited for treatment 
      with glasdegib plus LDAC and the management during therapy with this combination. 
      The panel considered the impact of concomitant medications and comorbidities 
      during treatment with glasdegib plus LDAC, and discussed common adverse events 
      (AEs) associated with glasdegib plus LDAC. Management strategies for AEs 
      discussed by the panel included dose modifications, supportive care therapies, 
      and prophylactic treatments. Finally, the panel highlighted the importance of 
      patient communication and education regarding the possible AEs that may occur 
      during treatment.
FAU - Cortes, Jorge E
AU  - Cortes JE
AUID- ORCID: 0000-0002-8636-1071
AD  - Division of Hematology and SCT, Georgia Cancer Center, Augusta, GA, USA.
FAU - Candoni, Anna
AU  - Candoni A
AUID- ORCID: 0000-0003-4436-1310
AD  - University Hospital of Udine-ASUFC, Udine, Italy.
FAU - Clark, Richard E
AU  - Clark RE
AD  - Department of Molecular and Clinical Cancer Medicine, University of Liverpool, 
      Liverpool, UK.
FAU - Leber, Brian
AU  - Leber B
AD  - Division of Hematology and Thromboembolism, Department of Medicine, McMaster 
      University Medical Centre, Hamilton, Canada.
FAU - Montesinos, Pau
AU  - Montesinos P
AUID- ORCID: 0000-0002-3275-5593
AD  - Department of Hematology, Hospital Universitari i Politecnic La Fe, Valencia, 
      Spain.
AD  - CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
FAU - Vyas, Paresh
AU  - Vyas P
AD  - Weatherall Institute of Molecular Medicine, Oxford, UK.
FAU - Zeidan, Amer M
AU  - Zeidan AM
AD  - Yale School of Medicine, New Haven, CT, USA.
FAU - Heuser, Michael
AU  - Heuser M
AD  - Hannover Medical School, Hannover, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200924
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Benzimidazoles)
RN  - 0 (Phenylurea Compounds)
RN  - 04079A1RDZ (Cytarabine)
RN  - K673DMO5H9 (glasdegib)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Benzimidazoles
MH  - *Cytarabine/adverse effects
MH  - Humans
MH  - *Leukemia, Myeloid, Acute/complications/drug therapy
MH  - Phenylurea Compounds/therapeutic use
OTO - NOTNLM
OT  - Acute myeloid leukemia
OT  - adverse events
OT  - comorbidities
OT  - glasdegib
OT  - low-dose cytarabine
OT  - older patients
EDAT- 2020/09/25 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/09/24 05:24
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/09/24 05:24 [entrez]
AID - 10.1080/10428194.2020.1817445 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2020 Dec;61(14):3287-3305. doi: 10.1080/10428194.2020.1817445. 
      Epub 2020 Sep 24.